Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer ...

The FDA makes furthering moves in SCLC, ovarian, and breast cancers, and the value of remote clinical pharmacists is explored in community oncology.

Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...

The FDA has approved Evrysdi in tablet form for patients with spinal muscular atrophy aged 2 years and older who weigh more ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.

AstraZeneca (NASDAQ:AZN) stock received a positive assessment from UBS, as analyst Matthew Weston upgraded the pharmaceutical giant's rating from Neutral to Buy. The upgrade was accompanied by a ...

Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or ...

BofA Securities reiterated its Buy rating on AstraZeneca (NASDAQ:AZN:LN) (NASDAQ: AZN), with a steady price target of GBP145.00. The firm's positive stance is based on the pharmaceutical giant's ...